Quick Take Pegbelfermin BMS986036 a PEGylated Fibroblast Growth Factor 21 Analogue in Patients with NonAlcoholic Steatohepatitis A Randomised DoubleBlind PlaceboControlled Phase 2a Trial

Quick Take: Pegbelfermin (BMS-986036), a PEGylated Fibroblast Growth Factor 21 Analogue, in Patients with Non-Alcoholic Steatohepatitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2a Trial

06:00 EST 23 Dec 2018 | 2 Minute Medicine

Non-alcoholic steatohepatitis (NASH), the most common chronic liver disease in the United States, puts patients at increased risk of developing cirrhosis and hepatocellular carcinoma. Patients with NASH are also at an increased risk of experiencing cardiovascular events and overall mortality. Pegbelfermin (BMS-986036) is a PEGylated human fibroblast growth factor 21 (FGF21) that has been previously […]

More From BioPortfolio on "Quick Take: Pegbelfermin (BMS-986036), a PEGylated Fibroblast Growth Factor 21 Analogue, in Patients with Non-Alcoholic Steatohepatitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2a Trial"